Clinical trials
Completed Arthritis, Rheumatoid trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
101 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 3 |
| 2005 | 6 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2012 | 10 |
| 2013 | 3 |
| 2014 | 9 |
| 2015 | 6 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 8 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 8 |
| 2024 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 101 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 11 |
| Chinese University of Hong Kong | 9 |
| AbbVie | 5 |
| Jiangsu HengRui Medicine Co., Ltd. | 5 |
| Pfizer | 5 |
| Eli Lilly and Company | 3 |
| Peking University People's Hospital | 3 |
| Beijing VDJBio Co., LTD. | 2 |
| Bio-Thera Solutions | 2 |
| Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthritis, Rheumatoid | 101 |
| Osteoarthritis | 5 |
| Arthritis | 4 |
| Osteonecrosis | 3 |
| Crohn Disease | 1 |
| Developmental Dysplasia of the Hip | 1 |
| Dyspepsia | 1 |
| Femoral Neck Fractures | 1 |
| Gout | 1 |
| Hip Dislocation, Congenital | 1 |
Trials
Showing 1 to 25 of 101. Each trial links to its page on Pharma Observatory.
1 more trial matches. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.